What is HC Wainwright's Forecast for SGMO FY2024 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Research analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a research note issued to investors on Thursday, November 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will post earnings per share of ($0.43) for the year, down from their prior forecast of ($0.40). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' Q3 2025 earnings at ($0.04) EPS.

A number of other analysts also recently issued reports on the company. StockNews.com raised Sangamo Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. Barclays lifted their price target on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an "overweight" rating in a report on Thursday.

Sangamo Therapeutics Price Performance

Shares of SGMO traded down $0.16 during midday trading on Monday, hitting $1.89. The stock had a trading volume of 5,126,309 shares, compared to its average volume of 6,919,630. The company has a 50 day simple moving average of $1.33 and a two-hundred day simple moving average of $0.87. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18. The firm has a market cap of $394.35 million, a price-to-earnings ratio of -2.73 and a beta of 1.10.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million for the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same period in the previous year, the company posted ($0.34) earnings per share.

Institutional Trading of Sangamo Therapeutics

A number of institutional investors have recently bought and sold shares of SGMO. Renaissance Technologies LLC boosted its position in shares of Sangamo Therapeutics by 58.8% during the 2nd quarter. Renaissance Technologies LLC now owns 4,126,577 shares of the biopharmaceutical company's stock worth $1,479,000 after purchasing an additional 1,528,600 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Sangamo Therapeutics by 4.0% in the 1st quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company's stock worth $3,311,000 after acquiring an additional 192,385 shares during the last quarter. Marshall Wace LLP raised its holdings in shares of Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company's stock worth $207,000 after acquiring an additional 207,476 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Sangamo Therapeutics by 55.4% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 38,850 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System raised its holdings in shares of Sangamo Therapeutics by 61.1% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock worth $42,000 after acquiring an additional 23,650 shares during the last quarter. Institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.